IJC International Journal of Cancer
|
|
- Rose George
- 6 years ago
- Views:
Transcription
1 IJC International Journal of Cancer Adjuvant chemotherapy for patients with primary hepatocellular carcinoma: A meta-analysis Zhouying Zheng 1 *, Wenhua Liang 2 *, Dongping Wang 1 *, Paul M. Schroder 3, Weiqiang Ju 1, Linwei Wu 1, Zheng Zheng 1, Yushu Shang 1, Zhiyong Guo 1 and Xiaoshun He 1 1 Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China 2 Department of Cardiothoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China 3 University of Toledo College of Medicine, Toledo, OH Numerous studies have investigated the effects of adjuvant chemotherapy for primary hepatocellular carcinoma (HCC) patients. We conducted this analysis to evaluate the efficacy of adjuvant chemotherapy in HCC patients after hepatectomy. PubMed/ MEDLINE, EMBASE, Cochrane, and other databases were searched for eligible studies. The major endpoints were overall survival (OS) and disease-free survival (DFS). The pooled odds ratio (OR) was calculated using a random-effects model to summarize the results. In the meta-analysis of 13 randomized control trials (RCTs) and 35 observational studies with 4747 patients, hepatectomy plus adjuvant chemotherapy showed superiority over hepatectomy alone in 1-year DFS (OR , , p < 0.001), 3-year DFS (OR , , p < 0.001) and 5-year DFS (OR , , p < 0.001), as well as 1-year OS (OR , 95% confidence interval , p < 0.001), 3-year OS (OR , , p < 0.001) and 5-year OS (OR , , p < 0.001). Subgroup and sensitivity analysis revealed that only adjuvant TACE had significant survival benefits. The meta-analysis of studies involving patients with portal vein tumor thrombus (PVTT), but not other factors related to recurrence risk, revealed favorable outcomes of the Treatment arm over the Control arm. The present study shows that adjuvant chemotherapy can improve outcomes for HCC patients. The benefits of adjuvant TACE have been confirmed whereas the effects of other adjuvant chemotherapy modalities remain uncertain. Adjuvant chemotherapy is likely to be more applicable to certain patient populations for instance those with PVTT, but further research in identifying these patient factors is of importance for tailoring adjuvant therapies to individual patients in the future. Hepatocellular carcinoma (HCC) is the most common liver cancer and fifth leading cause of cancer death around the world, with 85% of the cases occuring in developing countries. 1 Surgical resection, a potential curative treatment, has been considered as the first-line treatment for operable HCC for the past few decades. 2,3 However, the recurrence rates Key words: hepatocellular carcinoma, chemotherapy, hepatectomy, recurrence, meta-analysis Abbreviations: CI: confidence interval; DFS: disease-free survival; HAIC: hepatic arterial infusion chemotherapy; HCC: hepatocellular carcinoma; NCCN: national comprehensive cancer network; OR: odds ratio; OS: overall survival; PVC: portal vein chemotherapy; PVCE: portal vein chemoembolization; PVTT: portal vein tumor thrombus; RCT: randomized controlled trial; SC: systemic chemotherapy; TACE: transcatheter hepatic arterial chemoembolization Additional Supporting Information may be found in the online version of this article. *Z. Zheng, W. Liang, and D. Wang contributed equally to this work. Grant sponsor: National High Technology Research and Development Program of China (863 Program); Grant number: 2012AA021008; Grant sponsor: Key Clinical Project from the Ministry of Health; Grant number: ; Grant sponsor: National Natural Science Foundation of China; Grant numbers: , , , ; Grant sponsor: Special Fund for Science Research by Ministry of Health; Grant number: ; Grant sponsor: Research Fund for the Doctoral Program of Higher Education of China by the Ministry of Education; Grant numbers: , , ; Grant sponsors: Science and Technology Planning Key Clinical Project of Guangdong Province; Grant number: 2011A ; Grant sponsor: Major Sci-tech Special Program of Science and Technology Planning Project of Guangzhou City; Grant number: 2012Y ; Grant sponsors: Science and Technology Project of Guangdong Province; Grant number: 2010B ; Grant sponsor: State Key Clinical Specialty Construction Project; Project by Division of Medical Service Management of the Ministry of Health (2010) DOI: /ijc History: Received 18 May 2014; Accepted 29 July 2014; Online 10 Sep 2014 Correspondence to: Xiaoshun He, Organ Transplant Center, the First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan Er Road, Guangzhou , China, gdtrc@126.com and Zhiyong Guo, Organ Transplant Center, the First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan Er Road, Guangzhou , China, rockyucsf1981@126.com Int. J. Cancer: 136, E751 E759 (2015) VC 2014 UICC
2 E752 Adjuvant chemotherapy for HCC: A meta-analysis What s new? There are numerous randomized control trials and observational studies investigating the effects of adjuvant chemotherapy for hepatocellular carcinoma (HCC) patients. The results remain controversial, however. Here, the authors conduct a metaanalysis of all available studies to evaluate the efficacy of adjuvant chemotherapy in patients with primary HCC. They show that adjuvant chemotherapy can improve outcomes for HCC patients. They confirm the benefits of adjuvant transcatheter hepatic arterial chemoembolization (TACE), whereas the effects of other adjuvant chemotherapy modalities remain uncertain. Notably, adjuvant chemotherapy appeared particularly beneficial for patients with portal vein tumor thrombus as a complication of their disease. after hepatic resection remains about 80% at 5 years. 4 Microscopic vascular invasion, intrahepatic metastasis, multicentric occurrence, and non-anatomical resection are predisposing factors to tumor recurrence. 5,6 Adjuvant chemotherapy has been one of the major modalities in treating cancers in recent decades. 7 In general, the majority of HCC tumors can be removed after hepatectomy, and the remnant part can be eliminated by chemotherapy. 8 The benefit of adjuvant chemotherapy in controlling tumor growth and decreasing recurrence has been showed in many other solid tumors like breast cancer and non-small cell lung cancer. 9 There are numerous randomized control trials (RCTs) and observational studies investigating the effects of adjuvant chemotherapy for HCC patients. However, the results of these studies have been controversial. Many individual studies have reported conflicting results and systematic reviews or metaanalyses have a limited number of included studies to evaluate the effects of adjuvant chemotherapy Furthermore, there are no statements regarding adjuvant chemotherapy for HCC patients after hepatectomy in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines Version for Hepatobiliary Cancers. 13 In addition, no metaanalyses, reviews, or systematic reviews have evaluated the benefits of all the major modalities of adjuvant chemotherapy. To address these issues, we conducted this meta-analysis of all available studies to evaluate the efficacy of adjuvant chemotherapy in patients with primary HCC. Methods Definitions of outcomes The primary outcome was disease-free survival (DFS), which was defined as the time from randomization (RCTs) or diagnosis (observational studies) until first recurrence or death by any cause. Living patients without disease were censored on the date of last follow-up. The secondary outcome was overall survival (OS), which was defined as the time from randomization (RCTs) or diagnosis (observational studies) until death by any cause. Patients who were still alive at the endpoints of the study were censored on the date of last follow-up. Study searching Sources such as MEDLINE, EMBASE, the Cochrane Library database, ISI Web of Science, and the China Journal Full-text Database were searched. We used a combination of the terms hepatocellular carcinoma, or hepatic cancer, or hepatic carcinoma, or hepatoma, or hepatocarcinoma, or hepatic neoplasm, or liver cancer, or liver carcinoma, or liver neoplasm and adjuvant chemotherapy, or postoperative chemotherapy. An additional search through Google Scholar and a manual search through published literature were performed. Two authors carried out the search independently. The search was not restricted by language or study date. Inclusion and exclusion criteria Trials were included in this meta-analysis if they met the following criteria: (i) The study subjects were primary HCC patients without metastases and other cancerous diseases; (ii) An integrated description of methods and baseline characteristics were provided; (iii) Data contained at least one item of 1-, 3-, 5-year DFS and OS, or DFS and OS curves that cover these time points; (iv) The studies were prospective RCTs and observational studies or retrospective observational studies comparing hepatectomy plus adjuvant chemotherapy (Treatment arm) with hepatectomy alone (Control arm). Trials were excluded if they met any of the following criteria: (i) case series, case reports, reviews and conference reports; (ii) duplicate publications; (iii) studies based on overlapping cohorts from the same institution; (iv) studies with patients undergoing pre-operative treatments, such as chemotherapy, embolization, radiotherapy, radiofrequency and immunotherapy; (v) Studies with statistically significant differences in clinicopathologic and baseline characteristics between the Treatment and Control arms. Note express software (Beijing Aegean Software Company, Beijing, China) was used to manage the information of all included studies. Duplicate references were removed. Two authors independently selected the related references, assessed their eligibility according to the inclusion and exclusion criteria, and any disagreement was solved by discussion. Data extraction and quality assessment We extracted data on author details, year of publication, study methods, participants characteristics, hepatic resection pattern, chemotherapy interventions, patient DFS and OS rate by using a data extraction form. Attempts were made to
3 Zheng et al. E753 Figure 1. Flow chart of study selection. contact the authors of the original articles for the missing data. We evaluated the quality of each study with the modified Jadad scale or modified Newcastle Ottawa Scale. Statistical analysis The data was analyzed by Review Manager 5.1 (The Cochrane Collaboration, 2011, The Nordic Cochrane Centre, Denmark). Treatment effects were expressed as odds ratios (OR) with 95% confidence intervals (CI) for dichotomous outcomes. The Mantel Haenszel analysis was used to assess the efficacy of adjuvant chemotherapy. Random-effects models were used to summarize the results. Heterogeneity between trials was analyzed by v 2 -test with significance set at p < The extent of inconsistency was assessed by I 2 statistic. If heterogeneity existed, an attempt to identify the causes was made using subgroup and sensitivity analyses when appropriate. The point estimate of OR was considered statistically significant at p < 0.05 levels or if the 95% CI did not include the value of 1. Graphical funnel plots were generated to visually assess a publication bias. The statistical methods to detect funnel plot asymmetry were the rank correlation test of Begg and Mazumdar and the regression asymmetry test of Egger. Results Characteristics of included studies Figure 1 illustrates the flow chart of study selection. There were 48 eligible studies, including 13 RCTs and 35 observational studies, with 4,747 participants included in this analysis. Among them, there were 2,235 patients from 19 studies included in the transcatheter hepatic arterial chemoembolization (TACE) group, 615 patients from 10 studies in the hepatic arterial infusion chemotherapy (HAIC) group, 288 patients from four studies in the portal vein chemotherapy (PVC) group, 481 patients from six studies in the systemic chemotherapy (SC) group, and 582 patients from eight studies in the Combined (combination of two or more adjuvant chemotherapy modalities) group. Five observational studies were identified concerning locoregional chemotherapy with unclear classification, and one evaluated portal vein chemotherapy with lipiodol embolism (PVCE). These studies fell into none of the groups mentioned above. Therefore, we included these six studies with 666 patients in the ELSE group. More detailed information and the clinical characteristics of the included studies are summarized in Supporting Information Table 1. According to the pre-established criteria, we performed a quality assessment of each study with modified Jadad Scale or modified Newcastle Ottawa Scale (Supporting Information Tables 2 4). Seven RCTs, the scores of which were less than 4 in the modified Jadad Scale, were considered to be of low quality. Other RCTs and all of the observational studies were of high quality. Considering of the above, we conducted a subgroup analysis according to the quality of each study. Meta-analysis of all included studies Thirteen RCTs and 35 observational studies were included in this analysis, which contained 53 comparisons between the Treatment arm and Control arm. The pooled results showed significant improvement in 1-year DFS (OR , 95% CI , p < 0.001) (Fig. 2), 3-year DFS (OR , , p < 0.001) (Fig. 3), and 5-year DFS (OR , , p < 0.001) (Fig. 4) without statistically significant heterogeneity identified in the analysis of DFS. In the assessment of OS, the pooled results revealed statistically significant improvement in 1-year OS (OR , , p < 0.001) (Fig. 5), 3-year OS (OR , , p < 0.001) (Fig. 6), and 5-year OS (OR , , p < 0.001) (Fig. 7) without statistically significant heterogeneity identified in the analysis of 1-year OS (p , I %) or 3-year OS (p , I %), but there was heterogeneity identified in the analysis of 5-year OS (p , I %). Subgroup analysis and sensitivity analysis Although no significant heterogeneity was observed in most of the comparisons, we sought to minimize the potential
4 E754 Adjuvant chemotherapy for HCC: A meta-analysis Figure 2. Meta-analysis of 1-year DFS in all included studies comparing hepatectomy plus adjuvant chemotherapy (Treatment) with hepatectomy heterogeneity and probe into detailed results in the subpopulation by performing a subgroup analysis and a sensitivity analysis. We stratified the analyses according to several important confounding factors, which were believed to have significant effects on the results of a study including study design (RCTs or non-rcts), modalities of adjuvant chemotherapy (TACE, HAIC, PVC, SC, Combined and ELSE group), complication of portal vein tumor thrombus (PVTT; all, some or none of the patients), multiple tumor (more than 50% of the patients complicated or not), mean tumor size (larger than 5cm or not), complication of cirrhosis (more than 50% of the patients complicated or not), TNM stage (more than 50% of the patients in stage I and II or III and IVA), and the quality assessment of each study (low or high quality). Supporting Information Table 5 summarizes all of the subgroup results and overall results. The results of RCTs or non-rcts were similar to the overall results, while the outcomes of 1-year DFS and 5-year OS from RCTs revealed no statistically significant difference between the treatment arm and control arm. As to the subgroup results of adjuvant chemotherapy modalities, TACE showed significant improvement in 1-year DFS (OR , , p ) and OS (OR , , p < 0.001), 3-year DFS (OR , , p < 0.001) and OS (OR , , p < 0.001), 5-year DFS (OR , , p ) and OS (OR , , p ) with significant heterogeneity only identified in 5-year OS (p , I %) across studies. The results of HAIC treatment showed favorable outcomes of 1-, 3-, 5-year DFS and 3-, 5-year OS compared to the Control arm. However, most of these results were derived from observational studies. In addition, the pooled results of other adjuvant chemotherapy modalities remained undetermined because there were a limited number of RCTs and observational studies reporting results for these therapies that met the inclusion criteria. In terms of the subgroup results of those studies involving patients with PVTT (either all or some of the patients in the study) as a complication of their disease course (PVTT group), the analysis revealed favorable outcomes in the Treatment arm compared to the Control arm, while the results of other studies (non-pvtt group) did not. Importantly, the pooled OR values of the analysis of the PVTT group were higher than those of the non-pvtt group and the overall results in most of the outcomes. Moreover, we carried out a meta-analysis of
5 Zheng et al. E755 Figure 3. Meta-analysis of 3-year DFS in all included studies comparing hepatectomy plus adjuvant chemotherapy (Treatment) with hepatectomy Figure 4. Meta-analysis of 5-year DFS in all included studies comparing hepatectomy plus adjuvant chemotherapy (Treatment) with hepatectomy C 2014 UICC Int. J. Cancer: 136, E751 E759 (2015) V
6 Adjuvant chemotherapy for HCC: A meta-analysis E756 Figure 5. Meta-analysis of 1-year OS in all included studies comparing hepatectomy plus adjuvant chemotherapy (Treatment) with hepatectomy those studies in which all the included patients had a disease course complicated with PVTT. It showed an obviously significant improvement of DFS (OR , , p ) (Supporting Information Fig. 1) and OS (OR , , p < 0.001; Supporting Information Fig. 2) without statistically significant heterogeneity. According to the quality assessment of each study, we performed a subgroup analysis, most of the results are consistent with the overall results except the subgroup result of low quality in 5-year DFS. Also, we observed that most studies reported adjuvant chemotherapy tended to improve the patient s prognosis after hepatectomy. This was true for all studies except the studies reported by Lai et al. and Hasegawa et al. When we excluded the Lai et al. study, heterogeneity was significantly reduced in 3-year DFS (p C 2014 UICC Int. J. Cancer: 136, E751 E759 (2015) V
7 Figure 6. Meta-analysis of 3-year OS in all included studies comparing hepatectomy plus adjuvant chemotherapy (Treatment) with hepatectomy value increased from 0.01 to 0.32 and I2 dropped from 43 to 11%), and the pooled OR increased from 2.37 ( ) to 2.45 ( ). In addition, when we left the Hasegawa et al. study out, homogeneity was improved in 5-year OS (p value increased from to 0.02 and I2 dropped from 53 to 43%), and the pooled OR increased from 1.92 ( ) to 2.04 ( ) in 5-year OS. Publication bias The meta-analysis of 1-, 3-year DFS and 3-, 5-year OS showed potential publication biases with the p values lower than 0.05 given by Begg s or Egger s test. There was no evidence of pubc 2014 UICC Int. J. Cancer: 136, E751 E759 (2015) V lication bias for other results, as the funnel plot analysis showed a symmetrical appearance and p value ranging from 0.26 to 0.88 given by Begg s test and p value ranging from 0.46 to 0.69 by Egger s test (Supporting Information Fig. 3). Discussion In the meta-analysis of all included studies, we found that adjuvant chemotherapy was significantly superior to Control arm with higher 1-, 3-, 5-year DFS and OS. The pooled results of RCTs revealed statistically significant improvement of patients in the Treatment arm compared to the Control arm in all DFS and OS except 1-year DFS and 5-year OS. Our results E757 Zheng et al.
8 E758 Adjuvant chemotherapy for HCC: A meta-analysis Figure 7. Meta-analysis of 5-year OS in all included studies comparing hepatectomy plus adjuvant chemotherapy (Treatment) with hepatectomy provide evidence that adjuvant chemotherapy after hepatectomy provides benefits for operable HCC patients. However, distinct modalities of adjuvant chemotherapy may yield different patient outcomes. The meta-analyses of all included studies and only RCTs concerning TACE show improved 1-,3-, 5-year DFS and OS. The subgroup analysis results of adjuvant HAIC are similar to those of TACE. However, the meta-analysis of only RCTs concerning HAIC is not applicable with no more than one study included. The pooled OR values of HAIC in 1-, 5- yeardfsand3-,5-yearosarehigherthanthatoftace,but withlowerorvaluesin3-yeardfsand1-yearos.somestudies have compared the efficacy between TACE and HAIC in patients not receiving hepatectomy, indicating that chemotherapy drugs and patient selection may affect the outcomes of patients undergoing TACE and HAIC therapies. 14,15 Therefore, it is difficult to determine which one is better based on the current studies, and it is of interest to carry out studies directly comparing adjuvant TACE with HAIC in the future. In the subgroup analysis of adjuvant SC, the superior results of the Treatment arm were revealed in 3-, 5-year DFS and 3- year OS in comparison to the Control arm. Considering the small number of included studies, the efficacy of adjuvant SC is not yet clear and needs to be confirmed in future studies. On the other hand, with the growing knowledge of the molecular pathway of carcinogenesis, oral molecular targeted agent therapies have become the blue ocean of cancer treatment. 16 Most notably, sorafenib has been approved as a standard treatment for patients with advanced and unresectable HCC in most countries worldwide. 17,18 Recently, a pilot study showed that setting sorafenib as adjuvant therapy for HCC to prevent early recurrence after hepatic resection could be a potential indication. 19 However, because of the small sample size of the study, the therapeutic potential of sorafenib has not yet been proven in HCC patients after resection. Similarly, the efficacy of combined chemotherapy is unclear based on the current analysis. Considering the anticancer agents of adjuvant chemotherapy in each study, the most frequently used anticancer agents for adjuvant chemotherapy are the different combinations of ADM, MMC, DDP, 5-Fu and their derivatives. Besides these traditional anticancer agents, the application of some new drugs such as oxaliplatin (OXA), hydroxycamptothecine (HCPT) and capecitabine have been investigated by researchers. It has been revealed that OXA-based chemotherapy is effective in advanced HCC and represented a viable option in these patients. 20 HCPT with a low concentration could induce hepatocyte-specific differentiation of cancer stem-like cells from HCC cell line. 21
9 Zheng et al. E759 Notably, metronomic capecitabine can be well tolerated by patients with advanced HCC and appears to have activity both in treatment-naive patients and in those previously treated with sorafenib. 22 These novel drugs provide alternatives to the traditional anticancer agents for HCC adjuvant chemotherapy. In terms of patient selection for adjuvant chemotherapy, we have conducted a subgroup analysis of those studies involving patients with and without PVTT as a complication of their disease. Only in patients with (but not without) PVTT, the benefit of adjuvant chemotherapy was confirmed. HCC patients with PVTT would be considered to be advanced stage of liver cancer, 23 which often leads to intrahepatic metastasis or recurrence. In agreement with this result, some studies have demonstrated that adjuvant TACE is thought to be more applicable to patients at high risk for recurrence. 8,24 We have conducted a further subgroup analysis of studies with distinct tumor characteristics including multiple tumors, mean tumor size, cirrhosis status, and TNM stage. However, we failed to document any of these factors affecting the pooled analysis results. Notably, the risks of adjuvant chemotherapy should be weighed against its benefits. Adjuvant chemotherapy, especially adjuvant systemic chemotherapy, may not be sensitive to the majority of HCC patients owing to the drug tolerance of cancerous cells. In addition, excessive adjuvant chemotherapy may suppress the immune system and promote the transfer of the liver cancer. Finally, adjuvant chemotherapy, especially chemoembolization, may cause hepatic parenchymal damage and decline the compensatory function of cirrhotic liver. All these factors would inevitably affect the longterm survival of HCC patients. 8 Although this meta-analysis summarizes all available eligible studies concerning the use of adjuvant chemotherapy for HCC patients, there are still some drawbacks of this study. First, the number of included RCTs was relatively small and not all studies described the method of randomization. Second, there was some significant heterogeneity that may come from different clinical baseline characteristics and intervention protocols between the included studies. Third, some studies only reported DFS rates while some only reported OS rates. Finally, the quality of life was not assessed in those that received chemotherapy. In consideration of the limitations above, the results and conclusions in this study should be interpreted with cautions. In conclusion, we demonstrate that adjuvant chemotherapy is an effective treatment to improve the prognosis of primary HCC patients who underwent hepatectomy. Among all the modalities of adjuvant chemotherapy, only the efficacy of TACE has been verified by both observational studies and RCTs. Notably, adjuvant chemotherapy may be particularly beneficial for patients with PVTT as a complication of their disease. Collectively, we recommend adjuvant chemotherapy for selected HCC patients after resection with a suitable chemotherapy modality and chemotherapeutic agents. References 1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000;32: Makuuchi M, Donadon M, Torzilli G. Hepatic resection for hepatocellular carcinoma in cirrhosis. Ann Ital Chir 2008;79: Ueno M, Uchiyama K, Ozawa S, et al. Adjuvant chemolipiodolization reduces early recurrence derived from intrahepatic metastasis of hepatocellular carcinoma after hepatectomy. Ann Surg Oncol 2011;18: Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003;38: Wu ZQ. Evaluation of postoperative adjuvant chemotherapy for hepatocellular carcinoma. J. Abdominal Surg 2001;14: Huang JD, Li YM, Lei ZM. Evaluation of preoperative or post-operative transarterial chemotherapy for primary liver carcinoma. J Evidence- Based Med 2007;7: Ren ZG. Postoperative adjuvant chemotherapy for hepatocellular carcinoma after resection. Oncol Prog 2005;3: Fukui T, Mitsudomi T. Postoperative adjuvant chemotherapy for lung, gastric, colorectal and breast cancer. Nippon Rinsho 2010;68: Chan ES, Chow PK, Tai B, et al. Neoadjuvant and adjuvant therapy for operable hepatocellular carcinoma. Cochrane Database Syst Rev 2000;2: CD Mathurin P, Raynard B, Dharancy S, et al. Metaanalysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma. Aliment Pharmacol Ther 2003;17: Zhong JH, Li LQ. Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: a meta-analysis. Hepatol Res 2010;40: National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers Version Okusaka T, Kasugai H, Shioyama Y, et al. Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase III trial. J Hepatol 2009;51: Kim HY, Kim JD, Bae SH, et al. A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma. Korean J Hepatol 2010,16: Woo HY, Heo J. Sorafenib in liver cancer. Expert Opin Pharmacother 2012;13: Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359: Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia- Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10: Wang SN, Chuang SC, Lee KT. Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: a pilot study. Hepatol Res / hepr Petrelli F, Coinu A, Borgonovo K, et al. Oxaliplatin-based chemotherapy: a new option in advanced hepatocellular carcinoma. A systematic review and pooled analysis. Clin Oncol (R Coll Radiol) 2014;26: Zhang Y, Song WJ, Zhang FQ, et al. Differentiation-inducing activity of hydroxycamptothecin on cancer stem-like cells derived from hepatocellular carcinoma. Dig Dis Sci 2011;56: Brandi G, de Rosa F, Agostini V, et al. Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study. Oncologist 2013;18: Mitsunobu M, Toyosaka A, Oriyama T, et al. Intrahepatic metastases in hepatocellular carcinoma: the role of the portal vein as an efferent vessel. Clin Exp Metastasis 1996;14: Li JQ, Zhang CQ, Zhang YQ, et al. Value of adjuvant transcatheter hepatic arterial chemoembolization after hepatectomy for primary liver carcinoma. Chin J Bases Clin Gen Surg 2006;13:
Conventional oral systemic chemotherapy for postoperative hepatocellular carcinoma: A systematic review
MOLECULAR AND CLINICAL ONCOLOGY 2: 1091-1096 Conventional oral systemic chemotherapy for postoperative hepatocellular carcinoma: A systematic review JIANHONG ZHONG, BANGDE XIANG, LIANG MA and LEQUN LI
More informationManagement of HepatoCellular Carcinoma
9th Symposium GIC St Louis - 2010 Management of HepatoCellular Carcinoma Overview Pierre A. Clavien, MD, PhD Department of Surgery University Hospital Zurich Zurich, Switzerland Hepatocellular carcinoma
More informationTranscatheter Arterial Chemoembolization to Treat Primary or Metastatic Liver Malignancies
Transcatheter Arterial Chemoembolization to Treat Primary or Metastatic Liver Malignancies Policy Number: 8.01.11 Last Review: 6/2018 Origination: 8/2005 Next Review: 6/2019 Policy Blue Cross and Blue
More informationMeta-Analysis of Randomized Controlled Trial in Treating Primary Liver Cancer by Fufang Kushen Injection Combined with TACE
4th International Conference on Sustainable Energy and Environmental Engineering (ICSEEE 2015) Meta-Analysis of Randomized Controlled Trial in Treating Primary Liver Cancer by Fufang Kushen Injection Combined
More informationCelsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging
Celsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging Ronnie T.P. Poon, MBBS, MS, PhD Chair Professor of Hepatobiliary and Pancreatic Surgery Chief of Hepatobiliary and Pancreatic Surgery
More informationHepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Staff Reviewers: Dr. Yoo Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer
More informationRESEARCH ARTICLE. Di-Ya Wang 1&, Lei Liu 2&, Xing-Shun Qi 3& *, Chun-Ping Su 4, Xue Chen 3, Xu Liu 3, Jiang Chen 3, Hong-Yu Li 3, Xiao-Zhong Guo 3 *
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.13.5573 Re-Resection versus TACE for Recurrent HCC - a Meta-Analysis RESEARCH ARTICLE Hepatic Re-resection Versus Transarterial Chemoembolization for the Treatment
More informationTitle: What is the role of pre-operative PET/PET-CT in the management of patients with
Title: What is the role of pre-operative PET/PET-CT in the management of patients with potentially resectable colorectal cancer liver metastasis? Pablo E. Serrano, Julian F. Daza, Natalie M. Solis June
More information6/16/2016. Treating Hepatocellular Carcinoma: Deciphering the Clinical Data. Liver Regeneration. Liver Regeneration
Treating : Deciphering the Clinical Data Derek DuBay, MD Associate Professor of Surgery Director of Liver Transplant Liver Transplant and Hepatobiliary Surgery UAB Department of Surgery Liver Regeneration
More informationHCC: Is it an oncological disease? - No
June 13-15, 2013 Berlin, Germany Prof. Oren Shibolet Head of the Liver Unit, Department of Gastroenterology Tel-Aviv Sourasky Medical Center and Tel-Aviv University HCC: Is it an oncological disease? -
More informationLiver resection for HCC
8 th LIVER INTEREST GROUP Annual Meeting Cape Town 2017 Liver resection for HCC Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre The liver is almost unique in that treatment of the
More informationMP Transcatheter Arterial Chemoembolization to Treat Primary or Metastatic Liver Malignancies
Medical Policy MP 8.01.11 BCBSA Ref. Policy: 8.01.11 Last Review: 07/25/2018 Effective Date: 07/25/2018 Section: Therapy Related Policies 7.01.75 Cryosurgical Ablation of Primary or Metastatic Liver Tumors
More informationHCC with Intrahepatic Portal vein Tumour Should Be Treated by Systemic Therapy Rather Than Transarterial Therapy (Pros)
HCC with Intrahepatic Portal vein Tumour Should Be Treated by Systemic Therapy Rather Than Transarterial Therapy (Pros) Yi-Hsiang Huang, MD, Ph.D. Professor, Division of Gastroenterology & Hepatology,
More informationUnmet needs in intermediate HCC. Korea University Guro Hospital Ji Hoon Kim
Unmet needs in intermediate HCC Korea University Guro Hospital Ji Hoon Kim BCLC HCC Stage 0 PST 0, Child Pugh A Stage A C PST 0 2, Child Pugh A B Stage D PST > 2, Child Pugh C Very early stage (0) 1 HCC
More informationEditorial on combination treatment beyond sorafenib alone for hepatocellular carcinoma with portal vein tumor thrombosis
Editorial Editorial on combination treatment beyond sorafenib alone for hepatocellular carcinoma with portal vein tumor thrombosis Sun Hyun Bae 1, Hee Chul Park 2,3 1 Department of Radiation Oncology,
More informationAssociation of mir-21 with esophageal cancer prognosis: a meta-analysis
Association of mir-21 with esophageal cancer prognosis: a meta-analysis S.-W. Wen 1, Y.-F. Zhang 1, Y. Li 1, Z.-X. Liu 2, H.-L. Lv 1, Z.-H. Li 1, Y.-Z. Xu 1, Y.-G. Zhu 1 and Z.-Q. Tian 1 1 Department of
More informationCorporate Medical Policy
Corporate Medical Policy Cryosurgical Ablation of Primary or Metastatic Liver Tumors File Name: Origination: Last CAP Review: Next CAP Review: Last Review: cryosurgical_ablation_of_primary_or_metastatic_liver_tumors
More informationA) PUBLIC HEALTH B) PRESENTATION & DIAGNOSIS
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary), April 2017 by Dr. Jenny Ko (Medical Oncologist, Abbotsford Centre, BC Cancer
More informationSorafenib for Advanced Hepatocellular Carcinoma
CED-SOS Advice Report 7 ARCHIVED 2012 Sorafenib for Advanced Hepatocellular Carcinoma J. Knox, R. Cosby, K. Chan, and M. Sherman A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer
More informationEfficacy of percutaneous radiofrequency ablation for the treatment of hepatocellular carcinoma
Efficacy of percutaneous radiofrequency ablation for the treatment of hepatocellular carcinoma R.N. Zheng 1,2 *, Z.J. You 2 *, S.H. Lin 2 *, J. Jia 2, Y.M. Cai 2, C. Liu 2, S. Han 3 and S.M. Wang 2 1 Department
More informationEmbolotherapy for Cholangiocarcinoma: 2016 Update
Embolotherapy for Cholangiocarcinoma: 2016 Update Igor Lobko,MD Chief, Division Vascular and Interventional Radiology Long Island Jewish Medical Center GEST 2016 Igor Lobko, M.D. No relevant financial
More informationHepatobiliary Malignancies Retrospective Study at Truman Medical Center
Hepatobiliary Malignancies 206-207 Retrospective Study at Truman Medical Center Brandon Weckbaugh MD, Prarthana Patel & Sheshadri Madhusudhana MD Introduction: Hepatobiliary malignancies are cancers which
More informationHEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT
HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT INTRODUCTION: Hepatocellular carcinoma (HCC): Fifth most common cancer worldwide Third most common cause of cancer mortality In Egypt: 2.3%
More informationHepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC
Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC Objectives Identify patient risk factors for hepatocellular carcinoma (HCC) Describe strategies
More informationSystematic reviews and meta-analyses of observational studies (MOOSE): Checklist.
Systematic reviews and meta-analyses of observational studies (MOOSE): Checklist. MOOSE Checklist Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease:
More informationEASL-EORTC Guidelines
Pamplona, junio de 2008 CLINICAL PRACTICE GUIDELINES: PARADIGMS IN MANAGEMENT OF HCC EASL-EORTC Guidelines Bruno Sangro Clínica Universidad de Navarra. CIBERehd. Pamplona, Spain Levels of Evidence according
More informationHepatocellular Carcinoma: Diagnosis and Management
Hepatocellular Carcinoma: Diagnosis and Management Nizar A. Mukhtar, MD Co-director, SMC Liver Tumor Board April 30, 2016 1 Objectives Review screening/surveillance guidelines Discuss diagnostic algorithm
More informationThe Expression of Beclin-1 in Hepatocellular Carcinoma and Non-Tumor Liver Tissue: A Meta-Analysis
The Expression of Beclin-1 in Hepatocellular Carcinoma and Non-Tumor Liver Tissue: A Meta-Analysis Zhiqiang Qin¹, Xinjuan Yu², Jinkun Wu¹, Mei Lin¹ 1 Department of Pathology, School of Basic Medicine,
More informationHepatocellular Carcinoma. Markus Heim Basel
Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749
More informationCancerous esophageal stenosis before treatment was significantly correlated to poor prognosis of patients with esophageal cancer: a meta-analysis
Original Article Cancerous before treatment was significantly correlated to poor prognosis of patients with cancer: a meta-analysis Han-Yu Deng 1,2#, Guha Alai 1#, Jun Luo 1#, Gang Li 1, Ze-Guo Zhuo 1,
More informationMultidisciplinary Treatment Strategies for Primary and Metastatic Liver Cancers
Multidisciplinary Treatment Strategies for Primary and Metastatic Liver Cancers Ching-Wei D. Tzeng, M.D. Assistant Professor Surgical Oncology University of Kentucky Markey Cancer Center Affiliate Network
More informationNIH Public Access Author Manuscript J Surg Res. Author manuscript; available in PMC 2011 May 18.
NIH Public Access Author Manuscript Published in final edited form as: J Surg Res. 2011 April ; 166(2): 189 193. doi:10.1016/j.jss.2010.04.036. Hepatocellular Carcinoma Survival in Uninsured and Underinsured
More informationTranscatheter hepatic arterial chemoembolization may be considered medically necessary to
Original Issue Date (Created): July 1, 2002 Most Recent Review Date (Revised): September 24, 2013 Effective Date: November 1, 2013 I. POLICY Hepatocellular carcinoma Transcatheter hepatic arterial chemoembolization
More informationRadiofrequency Ablation of Primary or Metastatic Liver Tumors
Radiofrequency Ablation of Primary or Metastatic Liver Tumors Policy Number: 7.01.91 Last Review: 9/2018 Origination: 2/1996 Next Review: 9/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC)
More informationOptimal management of HCC: in Asia
Optimal management of HCC: in Asia Kwang-Hyub Han, MD Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea Newly diagnosed HCC : > 70% occur
More informationAddictive Benefit of Transarterial Chemoembolization and Sorafenib in Treating Advanced Stage Hepatocelluar Carcinoma: Propensity Analysis
Addictive Benefit of Transarterial Chemoembolization and Sorafenib in Treating Advanced Stage Hepatocelluar Carcinoma: Propensity Analysis Gwang Hyeon Choi, Ju Hyun Shim*, Min-Joo Kim, Min-Hee Ryu, Baek-Yeol
More informationGut Online First, published on May 5, 2005 as /gut
Gut Online First, published on May 5, 2005 as 10.1136/gut.2005.069237 p53 gene (Gendicine ) and embolization overcame recurrent hepatocellular carcinoma Guan YS, Liu Y, Zhou XP, Li X, He Q, Sun L. Authors
More informationSelective Internal Radiation Therapy (SIRT) in the multimodal approach to Hepatocellular Carcinoma
Selective Internal Radiation Therapy (SIRT) in the multimodal approach to Hepatocellular Carcinoma International Course on THERANOSTICS and MOLECULAR RADIOTHERAPY Brussels, 4 october 2017 Vincent Donckier
More informationSurgical management of HCC. Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London
Surgical management of HCC Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London Global distribution of HCC and staging systems WEST 1. Italy (Milan,
More informationStudy Objective and Design
Randomized, Open Label, Multicenter, Phase II Trial of Transcatheter Arterial Chemoembolization (TACE) Therapy in Combination with Sorafenib as Compared With TACE Alone in Patients with Hepatocellular
More informationA New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Published online: March 9, 2017 Editorial A New Era of Systemic Therapy for Hepatocellular Carcinoma with Prof. M. Kudo Editor Liver Cancer Introduction The SHARP study in 2007 [1] and the Asia Pacific
More informationRadiation Therapy for Liver Malignancies
Outline Radiation Therapy for Liver Malignancies Albert J. Chang, M.D., Ph.D. Department of Radiation Oncology, UCSF March 23, 2014 Rationale for developing liver directed therapies Liver directed therapies
More informationAccepted Manuscript. Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: too alarming?
Accepted Manuscript Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: too alarming? Qing-Lei Zeng, Zhi-Qin Li, Hong-Xia Liang, Guang-Hua Xu, Chun-Xia
More informationDisclosure. Speaker name: Prof. Maciej Pech I have the following potential conflicts of interest to report:
Disclosure Speaker name: Prof. Maciej Pech I have the following potential conflicts of interest to report: Consulting Employment in industry Stockholder of a healthcare company Owner of a healthcare company
More informationThe Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page
The Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page 1674-1679 Radioembolization in Treatment of Hepatocellular Carcinoma with Portal Vein Invasion Elsahhar Ahmed Hetta, Osama Mohamed
More informationReliability of Echocardiography Measurement of Patent Ductus Arteriosus Minimum Diameter: A Meta-analysis
International Journal of Cardiovascular and Cerebrovascular Disease 4(): 15-19, 016 DOI: 10.13189/ijccd.016.04001 http://www.hrpub.org Reliability of Echocardiography Measurement of Patent Ductus Arteriosus
More informationMANAGEMENT OF COLORECTAL METASTASES. Robert Warren, MD. The Postgraduate Course in General Surgery March 22, /22/2011
MANAGEMENT OF COLORECTAL METASTASES Robert Warren, MD The Postgraduate Course in General Surgery March 22, 2011 Local Systemic LIVER TUMORS:THERAPEUTIC OPTIONS Hepatoma Cholangio. Neuroendo. Colorectal
More informationOriginal Article INTRODUCTION. pissn eissn X
pissn 2287-2728 eissn 2287-285X Original Article https://doi.org/10.3350/cmh.2016.0071 A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular
More informationSOMATOSTATIN RECEPTORS IN HEPATOCELLULAR CARCINOMA. Marie LEQUOY Saint-Antoine Hospital, Department of Hepatology, Paris, France
SOMATOSTATIN RECEPTORS IN HEPATOCELLULAR CARCINOMA Marie LEQUOY Saint-Antoine Hospital, Department of Hepatology, Paris, France Somatostatin : SST Somatostatin (SST) protein : 2 active forms (alternative
More informationTranscatheter Arterial Chemoembolization (TACE) to Treat Primary or Metastatic Liver Malignancies
Transcatheter Arterial Chemoembolization (TACE) to Treat Primary or Metastatic Liver Malignancies Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its
More informationIS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?
IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views
More informationHan-Yu Deng 1,2#, Chang-Long Qin 1#, Gang Li 2#, Guha Alai 2, Yidan Lin 2, Xiao-Ming Qiu 1, Qinghua Zhou 1. Original Article
Original Article Can lobe-specific lymph node dissection be an alternative to systematic lymph node dissection in treating early-stage non-small cell lung cancer: a comprehensive systematic review and
More informationNegative impact of low body mass index on liver cirrhosis patients with hepatocellular carcinoma
Li et al. World Journal of Surgical Oncology (2015) 13:294 DOI 10.1186/s12957-015-0713-4 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Negative impact of low body mass index on liver cirrhosis
More informationNatural History and Treatment Trends in Hepatocellular Carcinoma Subtypes: Insights From a National Cancer Registry
2015;112:872 876 Natural History and Treatment Trends in Hepatocellular Carcinoma Subtypes: Insights From a National Cancer Registry PETER L. JERNIGAN, MD, KOFFI WIMA, MS, DENNIS J. HANSEMAN, PhD, RICHARD
More informationTranscatheter Arterial Chemoembolization (TACE) to Treat Primary or Metastatic Liver Malignancies. Original Policy Date
MP 8.01.09 Transcatheter Arterial Chemoembolization (TACE) to Treat Primary or Metastatic Liver Malignancies Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date
More informationClinical Trials for Liver and Pancreatic Cancer in Taiwan
Japan - Taiwan Joint Symposium on Medical Oncology Session 6 Hepatobiliary and pancreatic cancers Clinical Trials for Liver and Pancreatic Cancer in Taiwan Li-Tzong Chen 1,2 *, Jacqueline Whang-Peng 1,3
More informationALPHA-FETOPROTEIN-L3 FOR DETECTION OF HEPATOCELLULAR CANCER
Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are dependent upon
More informationHepatocellular Carcinoma: A major global health problem. David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center
Hepatocellular Carcinoma: A major global health problem David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center Hepatocellular Carcinoma WORLDWIDE The #2 Cancer Killer Overall cancer
More informationTreatment of Hepatocellular Carcinoma. Andrew J. Muir, MD MHS Division of Gastroenterology Duke University Medical Center
Treatment of Hepatocellular Carcinoma Andrew J. Muir, MD MHS Division of Gastroenterology Duke University Medical Center Epidemiology of HCC: world The 5 th most common cancer worldwide > 500, 000 new
More informationReconsidering Liver Transplantation for HCC in a Era of Organ shortage
Reconsidering Liver Transplantation for HCC in a Era of Organ shortage Professor Didier Samuel Centre Hépatobiliaire Inserm-Paris Sud Research Unit 1193 Departement Hospitalo Universitaire Hepatinov Hôpital
More informationAmerican Journal of Internal Medicine
American Journal of Internal Medicine 2016; 4(3): 49-59 http://www.sciencepublishinggroup.com/j/ajim doi: 10.11648/j.ajim.20160403.12 ISSN: 2330-4316 (Print); ISSN: 2330-4324 (Online) The Effect of Dose-Reduced
More informationSurgical resection for hepatocellular carcinoma (HCC)
Surgical resection for hepatocellular carcinoma (HCC) Wojciech G Polak, MD, PhD, FEBS Department of Surgery, Division of HPB and Transplant Surgery, Erasmus MC, University Medical Center Rotterdam the
More informationHepatocellular carcinoma (HCC) is the most
Original Article / Biliary Hepatobiliary & Pancreatic Diseases International Prognosis of hepatocellular carcinoma with bile duct tumor thrombus after R0 resection: a matched study Ding-Ding Wang, Li-Qun
More informationManagement of Stage IV Colorectal Cancer: Expanding the Horizon
Management of Stage IV Colorectal Cancer: Expanding the Horizon May Tee, MD, MPH and Jan Franko, MD, PhD MercyOne Surgical Group (Mercy Surgical Affiliates) GI Oncology Conference 2019 March 1, 2019 Disclosures
More informationPrognostic factors for unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolisation combined with radiotherapy
Original Article Prognostic factors for unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolisation combined with radiotherapy Zhonghua Qi 1,2, Qianqian Zhao 3, Renben Wang
More informationHepatocellular Carcinoma in Qatar
Hepatocellular Carcinoma in Qatar K. I. Rasul 1, S. H. Al-Azawi 1, P. Chandra 2 1 NCCCR, 2 Medical Research Centre, Hamad Medical Corporation, Doha, Qatar Abstract Objective The main aim of this study
More informationHEPATOCELLULAR CARCINOMA N. A.OTHIENO ABINYA
HEPATOCELLULAR CARCINOMA N. A.OTHIENO ABINYA - One of the most common solid organ tumours worldwide. - A public health problem in parts of Asia and subsaharan Africa, with incidence upto 50/100,000 population/year.
More informationORIGINAL PAPER. Introduction. R. Lencioni, 1 J. Marrero, 2 A. Venook, 3 S.-L. Ye, 4 M. Kudo 5
ORIGINAL PAPER Design and rationale for the non-interventional Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafenib (GIDEON) study R. Lencioni,
More information3/22/2017. I will be discussing off label/investigational use of tivantinib for hepatocellular carcinoma.
Grant/Research Support - AbbVie, Conatus, Hologic, Intercept, Genfit, Gilead, Mallinckrodt, Merck, Salix, Shire, Vital Therapies Consultant AbbVie, Gilead, Merck Member, Scientific Advisory Board Vital
More informationGuidelines for SIRT in HCC An Evolution
Guidelines for SIRT in HCC An Evolution 2 nd Asia Pacific Symposium on Liver- Directed Y-90 Microspheres Therapy 1st November 2014, Singapore The challenge of HCC Surgery is potentially curative in early
More informationPortal Vein Invasion and the Role of Liver Directed Therapy. Matthew S Johnson MD FSIR Indiana University May 6, 2016
Portal Vein Invasion and the Role of Liver Directed Therapy Matthew S Johnson MD FSIR Indiana University May 6, 2016 Matthew Johnson, M.D., FSIR Stock: Endoshape Consultant/Advisory Board: Bayer, BTG,
More informationHepatocellular Carcinoma: Transplantation, Resection or Ablation?
Hepatocellular Carcinoma: Transplantation, Resection or Ablation? Roberto Gedaly MD Chief, Abdominal Transplantation Transplant Service Line University of Kentucky Nothing to disclose Disclosure Objective
More informationPaul Martin MD FACG. University of Miami
Paul Martin MD FACG University of Miami 1 Liver cirrhosis of any cause Chronic C o c hepatitis epat t s B Risk increases with Male gender Age Diabetes Smoking ~5% increase in HCV-related HCC between 1991-28
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews High-dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents and young adults with first
More informationA systemic review and meta-analysis for prognostic values of pretreatment lymphocyte-to-monocyte ratio on gastric cancer
831094EJI0010.1177/2058739219831094European Journal of InflammationLi et al. letter2019 Letter to the Editor A systemic review and meta-analysis for prognostic values of pretreatment lymphocyte-to-monocyte
More informationOriginal Article Relationship of different surgical margins with recurrence-free survival in patients with hepatocellular carcinoma
Int J Clin Exp Pathol 2015;8(3):3404-3409 www.ijcep.com /ISSN:1936-2625/IJCEP0004822 Original Article Relationship of different surgical margins with recurrence-free survival in patients with hepatocellular
More informationA study on clinicopathological features and prognostic factors of patients with upper gastric cancer and middle and lower gastric cancer.
Biomedical Research 2018; 29 (2): 365-370 ISSN 0970-938X www.biomedres.info A study on clinicopathological features and prognostic factors of patients with upper gastric cancer and middle and lower gastric
More informationPEER-REVIEW REPORT CLASSIFICATION LANGUAGE EVALUATION SCIENTIFIC MISCONDUCT CONCLUSION. [ Y] Accept [ ] Grade B: Very good
Reviewer s code: 03656588 Reviewer s country: China Date reviewed: 2017-06-08 [ ] Grade A: Excellent [ Y] Accept [ ] Grade B: Very good [ ] High priority for [ Y] Grade C: Good language [ ] Major revision
More informationTREATMENT ALGORITHM FOR HEPATOCELLULAR CARCINOMA
HCC treatment : A permanent challenge! TREATMENT ALGORITHM FOR HEPATOCELLULAR CARCINOMA Michel Ducreux, MD, PhD Paul Brousse University Hospital Gustave Roussy Institute Villejuif, FRANCE A low level of
More informationAssociation between the -77T>C polymorphism in the DNA repair gene XRCC1 and lung cancer risk
Association between the -77T>C polymorphism in the DNA repair gene XRCC1 and lung cancer risk B.B. Sun, J.Z. Wu, Y.G. Li and L.J. Ma Department of Respiratory Medicine, People s Hospital Affiliated to
More informationEffect of adjuvant interferon therapy on hepatitis B virus-related hepatocellular carcinoma: a systematic review
Yang et al. World Journal of Surgical Oncology (2016) 14:159 DOI 10.1186/s12957-016-0912-7 REVIEW Effect of adjuvant interferon therapy on hepatitis B virus-related hepatocellular carcinoma: a systematic
More informationHepatocellular carcinoma
Hepatocellular carcinoma Mary Ann Y. Huang, M.D., M.S., FAASLD Transplant hepatologist Peak Gastroenterology Associates Porter Adventist Hospital Denver, Colorado Background - Worldwide Hepatocellular
More informationLiver Cancer: Diagnosis and Treatment Options
Liver Cancer: Diagnosis and Treatment Options Fred Poordad, MD Chief, Hepatology University Transplant Center Professor of Medicine UT Health, San Antonio VP, Academic and Clinical Affairs, Texas Liver
More informationAssociation between the CYP11B2 gene 344T>C polymorphism and coronary artery disease: a meta-analysis
Association between the CYP11B2 gene 344T>C polymorphism and coronary artery disease: a meta-analysis Y. Liu, H.L. Liu, W. Han, S.J. Yu and J. Zhang Department of Cardiology, The General Hospital of the
More informationADJUVANT CHEMOTHERAPY FOR RECTAL CANCER
ESMO Preceptorship Programme Colorectal Cancer Barcelona November, 25-26, 2016 ADJUVANT CHEMOTHERAPY FOR RECTAL CANCER Andrés Cervantes Professor of Medicine OLD APPROACH TO RECTAL CANCER Surgical resection
More informationJinshui Zeng and Guoqiang Su *
Zeng and Su World Journal of Surgical Oncology (2018) 16:157 https://doi.org/10.1186/s12957-018-1458-7 REVIEW Open Access of the inferior mesenteric artery during sigmoid colon and rectal cancer surgery
More informationComplete Pathological Response for Unresectable Hepatocellular Carcinoma with a Fluorouracil- Based Regimen after Sorafenib Failure
www.journalofcancerology.com PERMANYER J Cancerol. 2015;2:29-33 JOURNAL OF CANCEROLOGY CLINICAL CASE Complete Pathological Response for Unresectable Hepatocellular Carcinoma with a Fluorouracil- Based
More informationSEQUENCING OF HCC TREATMENT. Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA
SEQUENCING OF HCC TREATMENT Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA February 2018 DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationWeekly Versus Triweekly Cisplatin-Based Chemotherapy Concurrent With Radiotherapy in the Treatment of Cervical Cancer
REVIEW ARTICLE Weekly Versus Triweekly Cisplatin-Based Chemotherapy Concurrent With Radiotherapy in the Treatment of Cervical Cancer A Meta-Analysis Xingxing Chen, MD,* Haizhou Zou, MD,Þ Huifang Li, MD,*
More informationReview Article Effect of Neoadjuvant Chemoradiotherapy with Capecitabine versus Fluorouracil for Locally Advanced Rectal Cancer: A Meta-Analysis
Gastroenterology Research and Practice Volume 2016, Article ID 1798285, 10 pages http://dx.doi.org/10.1155/2016/1798285 Review Article Effect of Neoadjuvant Chemoradiotherapy with Capecitabine versus Fluorouracil
More informationLocoregional treatment Session Oral Abstract Presentation Saulo Brito Silva
Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Background Post-operative radiotherapy (PORT) improves disease free and overall suvivallin selected patients with breast cancer
More informationAdvances in percutaneous ablation and systemic therapies for hepatocellular carcinoma
Advances in percutaneous ablation and systemic therapies for hepatocellular carcinoma Paris Hepatology Congress 2019 Pierre Nahon Service d Hépatologie Hôpital Jean Verdier Bondy Université Paris 13 INSERM
More informationSmall cell lung cancer (SCLC) accounts for approximately
ORIGINAL ARTICLE A Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated Extensive-Stage Small Cell Lung Cancer Jingwei
More informationSi Hyun Bae, 1,2,3 Do Seon Song, 1,2,3 Myeong Jun Song, 1,4 Woo Jin Chung, 1,5
Comparison of efficacy between hepatic arterial infusion chemotherapy and sorafenib in advanced hepatocellular carcinoma with portal vein tumor thrombosis 1,2,3 Si Hyun Bae, 1,2,3 Do Seon Song, 1,2,3 Myeong
More informationColon Cancer Liver Metastases: Liver-Directed Therapy
Colon Cancer Liver Metastases: Liver-Directed Therapy Shishir K. Maithel, MD FACS Assistant Professor of Surgery Division of Surgical Oncology Winship Cancer Institute Emory University August 10, 2014
More informationReview Article Prognostic Role of MicroRNA-200c-141 Cluster in Various Human Solid Malignant Neoplasms
Disease Markers Volume 2015, Article ID 935626, 19 pages http://dx.doi.org/10.1155/2015/935626 Review Article Prognostic Role of MicroRNA-200c-141 Cluster in Various Human Solid Malignant Neoplasms Xiao-yang
More informationLiver transplantation: Hepatocellular carcinoma
Liver transplantation: Hepatocellular carcinoma Alejandro Forner BCLC Group. Liver Unit. Hospital Clínic. University of Barcelona 18 de marzo 2015 3r Curso Práctico de Transplante de Órganos Sólidos Barcelona
More informationSatisfactory surgical outcome of T2 gastric cancer after modified D2 lymphadenectomy
Original Article Satisfactory surgical outcome of T2 gastric cancer after modified D2 lymphadenectomy Shupeng Zhang 1, Liangliang Wu 2, Xiaona Wang 2, Xuewei Ding 2, Han Liang 2 1 Department of General
More information蕾莎瓦 Nexavar 臨床試驗資料 (HCC 肝細胞癌 )
蕾莎瓦 Nexavar 臨床試驗資料 (HCC 肝細胞癌 ) 1 Sorafenib Improves Survival in Hepatocellular Carcinoma: Results of a Phase III Randomized, -Controlled Trial Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
More information